Top 10 Oncology Stocks to Buy Now

2. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 76

Bristol-Myers Squibb Company (NYSE:BMY) is placed second among the best cancer stocks on our list.

TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the analyst, investors find the stock appealing because to its low valuation and a “catalyst-rich” 2026.

Separately, on January 12, Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 SCOUT-HCM trial, which assessed Camzyos (mavacamten) in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), yielded positive topline results. With a safety profile comparable to that of adults, the study, the first Phase 3 evaluation of a cardiac myosin inhibitor in patients with oHCM aged 12 to <18, fulfilled its primary and many secondary endpoints.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical leader in oncology, advancing innovative immuno-oncology and targeted therapies across solid tumors and hematologic malignancies, supported by a deep clinical pipeline and a strong legacy in cancer research and development.